Das George-Huntington-Institut
Roche Studie Generation-HD1 stoppt weitere Dosierung
March 22, 2021

Die Firma Roche hat in einer Pressemeldung mitgeteilt, dass die Generation-HD1 Studie mit dem...

Read More
PROOF-HD phase III pivotal trial with Pridopidine
September 30, 2020

GHI will shortly start the pivotal phase III trial PROOF-HD with Pridopidine. Several studies...

Read More
SHIELD-HD Study of Triplet Therapeutics started at GHI
September 24, 2020

nan

Read More
Erreichbarkeit während der Umzugsphase
June 22, 2020

Liebe Patienten, Angehörige und Interessenten,

 

aufgrund des Umzugs sind die...

Read More
German University Newspaper DUZ acknowledges GHI as successful startup
March 5, 2020

The German University Newspaper (Deutsche Universitätszeitung DUZ) introduces the GHI as...

Read More
Dr. Reilmann presents in symposium at MDS 2019 in Nice
March 5, 2020

Dr. Reilmann (GHI) outlined the opportunities of quantitative endpoints for clinical trials...

Read More
IDEA-FAST consortium receives € 44 Mio. from EU IMI2/Horizon 2020 program - GHI partner
December 6, 2019

The IMI2 consortium IDEA-FAST receives € 44 Mio. funding in the Horizon 2020 programm of the...

Read More
WAVE Studie rekrutiert Teilnehmer am GHI
December 6, 2019

Ziel der WAVE-Studie ist eine spezifische Reduktion der Produktion von krankhaft verändertem...

Read More
PRIDE-HD Studie in Lancet Neurology publiziert - Q-Motor zeigt Effekt von Pridopidine!
May 25, 2019

Die PRIDE-HD Studie ist unter Federführung von Dr. Ralf Reilmann vom GHI in dem renomierten...

Read More
Construction of GHI's R&D-Campus started!
May 25, 2019

Construction has started for GHI's new home, the "R&D-Campus Münster" in the...

Read More
Roche Studie Generation-HD1 stoppt weitere Dosierung
March 22, 2021

Die Firma Roche hat in einer Pressemeldung mitgeteilt, dass die Generation-HD1 Studie mit dem...

Read More
PROOF-HD phase III pivotal trial with Pridopidine
September 30, 2020

GHI will shortly start the pivotal phase III trial PROOF-HD with Pridopidine. Several studies...

Read More
SHIELD-HD Study of Triplet Therapeutics started at GHI
September 24, 2020

nan

Read More
Erreichbarkeit während der Umzugsphase
June 22, 2020

Liebe Patienten, Angehörige und Interessenten,

 

aufgrund des Umzugs sind die...

Read More
IDEA-FAST consortium receives € 44 Mio. from EU IMI2/Horizon 2020 program - GHI partner
December 6, 2019

The IMI2 consortium IDEA-FAST receives € 44 Mio. funding in the Horizon 2020 programm of the...

Read More